How to Implement NMPA Announcement No. 52 of 2026? Registration Certificate Transition, Transition Period Management, and Practical Paths for Brand Owners After Class II Medical Device Classification Adjustments
Recently, industry attention on the NMPA Announcement No. 52 of 2026 has been noticeably rising. This document, published on May 29 and completing its public comment period on June 1, has brought the familiar topic of "classification adjustments" back into the spotlight — after product categories are upgraded or downgraded, how do registration certificates transition, how long is the transition period, how are old certificates cancelled, and how are new certificates obtained? The entire industry is waiting for a clear implementation path.
Announcement No. 52 clarifies this path. Whether you are a registrant, a contract manufacturer, or a brand owner planning to license an existing certificate, you need to thoroughly understand this document.
This article, combined with the Hunan Provincial Medical Products Administration's Announcement No. 30 of 2026 issued on July 10 (cancelling 59 medical device registration certificates) and Announcement No. 31 of 2026 issued on July 13 (June new registration catalog), will clearly explain three things: the impact of the new classification adjustment policy on Class II medical device products, key points for transition period management, and practical paths for brand owners.
I. What Exactly Does Announcement No. 52 Address
NMPA Announcement No. 52 of 2026, full title "Announcement of the National Medical Products Administration on Work Related to Medical Device Classification Adjustments", was issued alongside Announcement No. 53 (the revised "Procedures for Dynamic Adjustment of the Medical Device Classification Catalog").
The announcement primarily addresses four categories of issues:
- How to handle registration and filing after management category adjustments (e.g., Class II upgraded to Class III, Class II downgraded to Class I)
- How to complete supplementary procedures for products previously not managed as medical devices that are now adjusted to be managed as medical devices
- How to wind down existing products that are no longer managed as medical devices after adjustment
- How to set transition periods and how regulatory authorities implement oversight
Key timeline: - May 29, 2026: Published by NMPA - June 1, 2026: Public comment period completed, effective immediately - July 10: Hunan Provincial Medical Products Administration cancelled 59 registration certificates (Announcement No. 30 of 2026) - July 13: Hunan Provincial Medical Products Administration published the June 2026 new registration catalog (Announcement No. 31 of 2026)
Within less than two months, provincial medical products administrations were already implementing the new regulations. The pace is much faster than in previous years.
II. How Is the Transition Period Calculated — The Issue Brand Owners Care Most About
Article 10 of Announcement No. 52 (in the "Procedures for Dynamic Adjustment" supporting Announcement No. 53) clearly sets out the principles for transition periods:
General rule (products not requiring clinical trials): - Registration transition period is generally set at 2 years
General rule (products requiring clinical trials): - Registration transition period is generally set at 3 years
Special circumstances (transition periods exceeding 3 years may be set): - In principle, the transition period shall not exceed 5 years - Products urgently needed for regulation may have appropriately shortened public comment periods
Practical interpretation:
For example. Suppose a Class II medical device product is adjusted to Class III on June 1, 2026. Products not requiring clinical trials must complete Class III registration by June 1, 2028; products requiring clinical trials must complete it by June 1, 2029. If industry circumstances are special, the transition period can be extended to June 1, 2031, but in principle, no later.
What this means for brand owners: - For products with existing certificates, pay attention to the classification adjustment list in the announcement - If your product falls under the "no clinical trials required" category (most medical dressings, liquid dressings, and anti-snoring devices fall here), the 2-year transition period is tight - If your product falls under the "clinical trials required" category (injectables, implants, high-risk Class III), the 3-year transition period is the industry baseline
III. Registration Certificate Transition — How to Handle 3 Typical Scenarios
Scenario 1: Old certificate adjusted from higher to lower category (e.g., Class III downgraded to Class II)
Announcement No. 52 stipulates: for renewal upon expiry, apply for renewal registration or filing according to the adjusted category. The newly issued registration certificate will note the original registration certificate number in the remarks column.
Practical points: - Follow the new category process for renewal - The remarks column will retain the "original registration certificate number" for traceability - No need to redo clinical trials (provided the product has not undergone substantive changes)
Scenario 2: Old certificate adjusted from lower to higher category (e.g., Class II upgraded to Class III)
This is the most troublesome scenario. Announcement No. 52 stipulates: the original registration certificate shall not exceed the registration transition deadline specified in the classification adjustment document. The registrant must proactively cancel the original registration certificate, and the new certificate follows the full process under the higher category.
Practical points: - During the transition period, one renewal under the original category is permitted (provided the product is safe and effective with no serious adverse events after market launch) - After obtaining the new certificate, the original certificate is automatically cancelled (if not proactively cancelled, the original registration authority will forcibly cancel it) - Clinical trials will most likely need to be supplemented (higher category review requirements are stricter)
Scenario 3: Not managed as a medical device → managed as a medical device (e.g., certain cosmetics and medical auxiliary products are brought under medical device management)
Announcement No. 52 stipulates: from the transition deadline for registration/filing, products that have not obtained registration certificates or filings in accordance with the law shall not be manufactured, operated, or imported.
Practical points: - Registration or filing must be completed within the transition period - After the transition deadline, manufacturing, sales, and import are prohibited - Products already on the market must either be withdrawn or have procedures completed under the new regulations
IV. The Real Situation of Hunan Yian/Weptide — A Practical Case Study of the New Classification Adjustment Policy
Too much theory is boring. Let's use real data.
Case 1: Medical Recombinant Collagen Lyophilized Fiber — Xiangxie Zhun 20252140492 - Registrant: Hunan Yian Biotechnology Co., Ltd. - Production address: Building 11, Unit 501, Lanyuegu Intelligent Manufacturing Industrial Park, Xieyuan North Road, Ningxiang Economic and Technological Development Zone, Changsha, Hunan (changed to Building 11 on 2025-06-30) - Approval date: 2025-05-30, valid until 2030-05-29 - 2025 management category: Class II
If this product is included in classification adjustment in the future (e.g., adjusted to Class III or adjusted to Class I), per Announcement No. 52: - Upgraded to Class III: clinical trials must be supplemented within the transition period, Class III registration certificate must be obtained, original certificate cancelled - Downgraded to Class I: renewal upon expiry can be done as Class I filing, with the original certificate number retained in the remarks column
Case 2: Medical Recombinant Mussel Adhesive Protein Nasal Spray — Xiangxie Zhun 20262140244 - Registrant: Weptide Bioengineering (Hunan) Co., Ltd. - Contract manufacturer: Hunan Yian Biotechnology Co., Ltd. - Approval date: 2026-04-30, valid until 2031-04-29 - 2026 management category: Class II - This is a newly approved certificate from April 2026, just before Announcement No. 52 was published. Completing the entire classification adjustment transition process is a real test for both the contract manufacturer and the brand owner.
Case 3: Medical Gel Dressing — Xiangxie Zhun 20252140968 - Registrant: Weptide Bioengineering (Hunan) Co., Ltd. - Approval date: 2025-12-01 - Contract manufacturing: Hunan Yian Biotechnology - Gel composition: silk fibroin, sodium hyaluronate, ectoin - Newly approved in December 2025, published by Hunan Provincial Medical Products Administration in January 2026 (one of 89 new certificates)
V. Two Actions by Hunan Provincial Medical Products Administration in July — Regulation Is Already Being Enforced
Action 1: July 10, 2026, cancellation of 59 registration certificates (Announcement No. 30 of 2026)
In accordance with the "Regulations on the Supervision and Administration of Medical Devices," based on enterprise applications, the Hunan Provincial Medical Products Administration cancelled medical device registration certificates for 59 products from 9 enterprises. This is the first batch of centralized cleanup of "zombie certificates" by a provincial authority after the new classification adjustment policy took effect.
Reminders for brand owners: - If your registration certificate has not been used for a long time, proactively applying for cancellation is safer than being passively cleaned up - Reapplying after cancellation does not count as "fake certificates or reused certificates," and compliance risk is lower - If not proactively cancelled, the original registration authority will announce the cancellation, and a record will remain on your credit history
Action 2: July 13, 2026, publication of the June new registration catalog (Announcement No. 31 of 2026)
The catalog of newly approved Class II medical device products and newly added manufacturers in Hunan Province for June has been published. This means that under the new classification adjustment policy, regulatory approvals have not stopped — they have simply become stricter.
Reminders for brand owners: - The pace of new certificate approvals in the industry has not slowed down, but review requirements have clearly increased - Clinical evaluation documentation, similar product comparison documentation, and process validation documentation are the three major areas for supplementary corrections - Determine the evaluation pathway at the project initiation stage to avoid changing plans midway (a point repeatedly emphasized by Hunan Yian Biotechnology in internal reviews)
VI. 3 Practical Recommendations for Brand Owners
Recommendation 1: Keep the classification adjustment list "in your pocket"
Every time NMPA issues a new version of classification adjustment documents, screenshot and archive the section relevant to your products. Announcement No. 52 plus the dynamic adjustment mechanism supporting Announcement No. 53 means more product categories will be adjusted in the future. Having the list on hand means you won't panic when renewal time comes.
Recommendation 2: Plan early for transition period management
Classification adjustment is a "known unknown" — you know it will come, but not when. It is recommended to compile a table of all current Class II registration certificates with their approval dates, validity periods, and transition deadlines: - Expiring within 2 years: prioritize checking whether they will be adjusted, prepare renewal materials in advance - Expiring in 3-5 years: monitor industry trends, plan 6-12 months ahead - Expiring in 5+ years: no urgency for now, but maintain quarterly tracking
Recommendation 3: When selecting a contract manufacturer, evaluate "classification adjustment responsiveness"
Under the new classification adjustment policy, a contract manufacturer's registration response speed, clinical evaluation capability, and change filing experience directly determine the speed at which a brand owner's products reach the market.
Practical criteria: - Whether they have a dedicated registration team (not outsourced to a CRO) - Number of new certificates approved in the past 2 years (don't just look at historical accumulation; look at recent 2-year momentum) - Speed of handling change filings (production address changes and registrant address changes are common items) - Experience in selecting clinical evaluation pathways (similar product comparison vs. clinical trials)
The approach of Hunan Yian Biotechnology is worth referencing: in internal reviews, the business lead repeatedly emphasized "determine the evaluation pathway at the project initiation stage to avoid changing plans midway." These 14 characters are hard-earned experience.
VII. Final Thoughts
Announcement No. 52 of 2026 is not "another round of classification reform" — it clarifies "how classification reform will be implemented". Transition periods, registration certificate transitions, remarks column management, and cancellation mechanisms — every step has a clear path.
For brand owners, the new classification adjustment policy is not a flood or a beast. What it eliminates is non-compliant practices like "not renewing old certificates, not applying for new certificates, and not cleaning up zombie certificates." What it retains are the "long-termists" with strong compliance awareness, steady registration momentum, and solid clinical evaluation.
At this juncture in July 2026, the Hunan Provincial Medical Products Administration is already enforcing the new policy. Those holding certificates, those licensing certificates for white-labeling, and those working through contract manufacturing partnerships — all should pull out this document and read it again.
